The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
For more information, visit https://www.boehringer-ingelheim.com.au
Type 2 diabetes is a serious health issue with around one million diagnosed cases, of which half are also affected from renal impairment. This education module explores the pharmacological and non-pharamacological management of type 2 diabetes and its comorbities, with a focus on management options in patients with renal impairment.
Upon completion of this learning module, participants will be able to: